Case 4: Recurrent Ovarian Cancer, Platinum-Resistant, BRCA WT
Case 4: I-O Therapy for Platinum-Resistant Recurrent DiseaseПодробнее
Case 4: Treating Platinum-Resistant Recurrent DiseaseПодробнее
Recurrent Ovarian Cancer: Third-Line Therapy and BeyondПодробнее
Considerations for Managing Recurrent Ovarian CancerПодробнее
Case-Based Overview: Pretreated Recurrent Ovarian CancerПодробнее
Recurrent Ovarian Cancer: QUADRA TrialПодробнее
Emerging opportunities in platinum-resistant recurrent ovarian cancerПодробнее
Olaparib Maintenance for Recurrent Ovarian CancerПодробнее
Case 3: Maintenance Therapy for Recurrent Ovarian CancerПодробнее
Strategies for Managing Recurrent Ovarian CancerПодробнее
Relacorilant + nab-paclitaxel in recurrent, platinum-resistant ovarian cancerПодробнее
Case 3: Second-Line Therapy for Recurrent Ovarian CancerПодробнее
Recurrent Ovarian Cancer: Novel Agents Under InvestigationПодробнее
Case Study: Platinum Sensitive Recurrent High-Grade Serous Ovarian CancerПодробнее
Ovarian Cancer: Testing for BRCA MutationsПодробнее
Bevacizumab in Platinum-Resistant Ovarian CancerПодробнее
Dr. Arend on Unmet Needs in Platinum-Resistant Ovarian CancerПодробнее
Recurrent Advanced Ovarian Cancer: Case ImpressionsПодробнее
Case 3: PARP Inhibition in Recurrent Ovarian CancerПодробнее
Dr. Matulonis Discusses Niraparib/Pembrolizumab Combo in Platinum-Resistant Ovarian CancerПодробнее